Megan Miller-Kassamali

5PUBLICATIONS
33CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)PharmacogenomicsRheumatology and arthritisGeriatrics and gerontology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Aug 28, 2026
Safety of Icotrokinra Through 1 Year for the Treatment of Moderate-to-Severe Plaque Psoriasis and Psoriasis Affecting High-Impact Sites: Pooled Results Across the ICONIC-LEAD, ICONIC-TOTAL, and ICONIC-ADVANCE 1 and 2 Phase 3 Trials.

|Jun 02, 2026
Guselkumab Safety in Patients With Latent Tuberculosis: Analysis of 11 Studies in Psoriatic Disease.

|Oct 31, 2023
Long-Term Safety of Guselkumab in Patients with Psoriatic Disease: An Integrated Analysis of Eleven Phase II/III Clinical Studies in Psoriasis and Psoriatic Arthritis.

Bruce Strober, Laura C Coates, Mark G Lebwohl

|Jun 09, 2021
Five-year maintenance of clinical response and health-related quality of life improvements in patients with moderate-to-severe psoriasis treated with guselkumab: results from VOYAGE 1 and VOYAGE 2.

K Reich, K B Gordon, B E Strober

|Sep 10, 2020
Maintenance of Response Through up to 4 Years of Continuous Guselkumab Treatment of Psoriasis in the VOYAGE 2 Phase 3 Study.

Kristian Reich, April W Armstrong, Peter Foley

Pageof 1

Frequent Collaborators

2 joint publications

Kristian Reich

2 joint publications

Kenneth B Gordon

2 joint publications

Bruce Strober

2 joint publications

April W Armstrong